EP Patent

EP3438106A1 — Anti-viral compounds

Assigned to AbbVie Ireland ULC · Expires 2019-02-06 · 7y expired

What this patent protects

This invention relates to processes and intermediates for making compounds which are effective in inhibiting replication of Hepatitis C virus (HCV).

USPTO Abstract

This invention relates to processes and intermediates for making compounds which are effective in inhibiting replication of Hepatitis C virus (HCV).

Drugs covered by this patent

Patent Metadata

Patent number
EP3438106A1
Jurisdiction
EP
Classification
—
Expires
2019-02-06
Drug substance claim
No
Drug product claim
No
Assignee
AbbVie Ireland ULC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.